首页 > 市场调查报告书 > 製药

DDS

市场调查报告书

商品编码

1517635

口服固体製剂合约製造市场- 按产品（片剂、胶囊、粉末）、类型（立即、延迟和控释）、治疗领域（肿瘤、心血管、感染、代谢）、服务、最终用途、全球预测（2024年） - 2032)

Oral Solid Dosage Contract Manufacturing Market - By Product (Tablet, Capsule, Powder), Type (Immediate, Delayed, & Controlled Release), Therapeutic area (Oncology, Cardiovascular, Infectious, Metabolic), Service, End-use, Global Forecast (2024 - 2032)

出版日期: 2024年04月24日 | 出版商:

Global Market Insights Inc. | 英文 195 Pages | 商品交期: 2-3个工作天内

价格

简介目录

口服固体剂型合约製造市场规模预计在2024 年至2032 年期间复合年增长率将达到5.6%。组织(CMO)降低成本，提高生产效率，专注于研发活动等核心能力。对于那些希望在不投资大量生产设施的情况下扩大经营规模的中小型製药公司来说，这一点尤其突出。

对仿製药的需求也将影响市场的成长。随着品牌药物的专利到期，为了满足全球医疗保健需求，仿製药的生产激增。口服固体剂型是最常用的药物之一，因为它们提供配方开发、法规遵循和生产规模扩大方面的专业知识。技术和品质标准的不断进步，以确保一致的产品品质和遵守严格的监管要求，也刺激了市场的成长。例如，2024 年 4 月，Lupin 在获得 FDA 批准后在美国推出了米拉贝隆缓释片（25 毫克）。

整个产业分为产品、类型、治疗领域、服务、最终用途和地区。

从产品来看，胶囊领域的口服固体製剂合约製造市场预计到 2032 年将大幅成长，因为胶囊作为製药公司和消费者的首选剂型越来越受欢迎。胶囊具有许多优点，包括易于吞嚥、更好的生物利用度以及能够封装多种药物製剂，包括粉末、颗粒和液体。这种多功能性使它们成为各种治疗应用的理想选择。

在服务方面，API製造领域的口服固体製剂合约製造业预计将在2024年至2032年期间产生可观的收入。这是因为 API（活性药物成分）在药物功效和配方中发挥关键作用。随着製药公司努力开发更有效、更有针对性的疗法，对符合严格监管标准的高品质 API 的需求不断增加。

亚太地区口服固体製剂合约製造市场将在 2024 年至 2032 年期间产生利润丰厚的成长。这归因于印度和中国製造商提供的巨大成本优势，与西方国家相比，它们以更低的成本提供高品质的产品。在医疗保健基础设施和研发活动投资增加的支持下，製药业的快速扩张也刺激了对合约製造服务的需求。人口众多且不断增长，加上医疗保健支出不断增加和慢性病的流行，进一步增加了对负担得起且可获得的药物的需求，推动了区域行业的扩张。

产业生态系统分析
产业影响力
- 成长动力
  - CDMO 越来越多地采用外包製造活动
  - 对仿製药的需求不断增加
  - 製药公司与 CDMO 之间的策略合作伙伴关係不断增加
- 产业陷阱与挑战
  - 品质控制挑战
  - 智慧财产权问题
成长潜力分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
平板电脑
胶囊
粉末
颗粒剂
其他产品

第 6 章：市场估计与预测：按类型，2021 - 2032

主要趋势
立即发布
延迟发布
控制释放

第 7 章：市场估计与预测：按治疗领域，2021 - 2032 年

主要趋势
肿瘤学
心血管疾病
代谢紊乱
神经系统疾病
传染性疾病
胃肠道疾病
其他治疗领域

第 8 章：市场估计与预测：按服务分类，2021 - 2032 年

主要趋势
药品开发
填充成品製造
原料药製造
包装和标籤
其他应用

第 9 章：市场估计与预测：依最终用途，2021 - 2032 年

主要趋势
大型企业
中小型企业

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Aenova Group
AbbVie Contract Manufacturing (AbbVie Inc.)
Boehringer Ingelheim International GmbH
Catalent, Inc.
Corden Pharma International
Jubilant Pharmova Limited
Lonza
NextPharma Technologies
Patheon Pharma Services (Thermo Fisher Scientific Inc.)
Siegfried Holding AG

简介目录

Product Code: 9169

Oral solid dosage contract manufacturing market size is expected to record 5.6% CAGR between 2024 and 2032. Lately, pharmaceutical companies are increasingly outsourcing the production of oral solid dosage forms, such as tablets, capsules, and powders to contract manufacturing organizations (CMOs) to reduce costs, improve production efficiency, and focus on core competencies like R&D activities. This is particularly prominent among small to mid-sized pharmaceutical firms looking to scale operations without investing in extensive manufacturing facilities.

The demand for generic drugs will also influence the market growth. As patents for branded drugs expire, there is a surge in the production of generic versions to meet the healthcare demands worldwide. Oral solid dosage forms are among the most prescribed medications as they offer expertise in formulation development, regulatory compliance, and manufacturing scale-up. Rising advancements in technology and quality standards to ensure consistent product quality and adherence to stringent regulatory requirements are also stimulating the market growth. For instance, in April 2024, Lupin unveiled Mirabegron extended-release tablets (25 mg) in the U.S. after approval from FDA.

The overall industry is segmented into product, type, therapeutic area, service, end-use, and region.

Based on product, the oral solid dosage contract manufacturing market from the capsules segment is expected to witness substantial growth rate through 2032 due to its increasing popularity as a preferred dosage form for both pharmaceutical companies and consumers. Capsules offer numerous advantages, including ease of swallowing, better bioavailability, and the ability to encapsulate a wide range of drug formulations, including powders, granules, and liquids. This versatility makes them ideal for a variety of therapeutic applications.

In terms of service, the oral solid dosage contract manufacturing industry from the API manufacturing segment is slated to generate notable revenue during 2024-2032. This is due to the critical role played by APIs (active pharmaceutical ingredients) in drug efficacy and formulation. As pharmaceutical companies strive to develop more effective and targeted therapies, there is an increasing demand for high-quality APIs that meet stringent regulatory standards.

Asia Pacific oral solid dosage contract manufacturing market will generate lucrative growth during 2024-2032. This is attributed to the substantial cost advantages offered by manufacturers in India and China, which provide high-quality production at lower costs compared to Western countries. The rapid expansion of the pharmaceutical industry, supported by increasing investments in healthcare infrastructure and R&D activities, is also fueling the demand for contract manufacturing services. The large and growing population, coupled with rising healthcare expenditure and the prevalence of chronic diseases, is further increasing the need for affordable and accessible medications, driving the regional industry expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising adoption of CDMOs for outsourcing manufacturing activities
  - 3.2.1.2 Increasing demand for generic drugs
  - 3.2.1.3 Growing number of strategic partnerships between pharmaceutical companies and CDMOs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Quality control challenges
  - 3.2.2.2 Intellectual property concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Tablets
5.3 Capsules
5.4 Powders
5.5 Granules
5.6 Other products

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Immediate release
6.3 Delayed release
6.4 Controlled release

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oncology
7.3 Cardiovascular diseases
7.4 Metabolic disorders
7.5 Neurological disorders
7.6 Infectious diseases
7.7 Gastrointestinal diseases
7.8 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Drug product development
8.3 Fill finish product manufacturing
8.4 API manufacturing
8.5 Packaging and labelling
8.6 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Large size companies
9.3 Medium & small size companies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa